Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated-PI3Kα in early and advanced HER2-positive breast cancer.

Lin-Wei GuoXiao-Guang LiYun-Song YangXun-Xi LuXiang-Chen HanGuan-Tian LangLi ChenZhi-Ming ShaoXin Hu

Published in: Clinical and translational medicine (2022)

We proposed adaptive treatment strategies that the mutated PIK3CA and amplified ERBB2 should be concomitantly inhibited when exposing to continuous anti-HER2 therapy, while the combination of anti-HER2 and anti-PI3Kα treatment was not essential for anti-HER2 treatment-naïve patients. These findings improve the understanding of genomics-guided treatment in the different progressions of HER2+ breast cancer.

Keyphrases

positive breast cancer
single cell
stem cells
gene expression
copy number
tyrosine kinase
prognostic factors
cancer therapy
patient reported